Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Research And Development Expense of $921.93 million for the year ending 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +23.4% in Research And Development Expense from 2024 to 2025.
- This data is from BIOMARIN PHARMACEUTICAL INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $35.65 million | Q3 2010: $39.37 million | Q1 2011: $45.02 million | Q2 2011: $52.91 million | Q3 2011: $58.58 million | Q1 2012: $73.83 million | Q2 2012: $77.81 million | Q3 2012: $66.21 million | Q1 2013: $83.74 million | Q2 2013: $85.66 million | Q3 2013: $88.06 million | Q1 2014: $86.17 million | Q2 2014: $107.70 million | Q3 2014: $125.69 million | Q1 2015: $142.07 million | Q2 2015: $157.90 million | Q3 2015: $158.71 million | Q1 2016: $158.79 million | Q2 2016: $167.04 million | Q3 2016: $160.83 million | Q1 2017: $145.00 million | Q2 2017: $143.04 million | Q3 2017: $154.10 million | Q1 2018: $183.95 million | Q2 2018: $175.58 million | Q3 2018: $161.41 million | Q1 2019: $183.59 million | Q2 2019: $185.64 million | Q3 2019: $172.96 million | Q1 2020: $142.26 million | Q2 2020: $182.14 million | Q3 2020: $147.05 million | Q1 2021: $148.73 million | Q2 2021: $161.11 million | Q3 2021: $157.87 million | Q1 2022: $160.84 million | Q2 2022: $158.19 million | Q3 2022: $157.83 million | Q1 2023: $171.85 million | Q2 2023: $177.36 million | Q3 2023: $191.31 million | Q1 2024: $204.99 million | Q2 2024: $183.79 million | Q3 2024: $184.90 million | Q1 2025: $158.73 million | Q2 2025: $161.31 million | Q3 2025: $409.48 million.
- Over the full 18 years of available data (2008 to 2025), BIOMARIN PHARMACEUTICAL INC's Research And Development Expense has grown by 888.2%.
- Historical annual values: Fiscal year 2025: $921.93 million | Fiscal year 2024: $747.18 million | Fiscal year 2023: $746.77 million | Fiscal year 2022: $649.61 million | Fiscal year 2021: $628.79 million | Fiscal year 2020: $628.12 million | Fiscal year 2019: $715.01 million | Fiscal year 2018: $696.33 million | Fiscal year 2017: $610.75 million | Fiscal year 2016: $661.91 million | Fiscal year 2015: $634.81 million | Fiscal year 2014: $461.54 million | Fiscal year 2013: $354.78 million | Fiscal year 2012: $302.22 million | Fiscal year 2011: $214.37 million | Fiscal year 2010: $147.31 million | Fiscal year 2009: $115.12 million | Fiscal year 2008: $93.29 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: